Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700048 · ClinicalTrials.gov registry record · Phase 1
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
A Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02700048: Clinical Trial Phase 1 study, sponsored by University of Minnesota.
NCT02700048 is a Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700048, a Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 individuals to obtain the complete data sets from 15 participants. Expected duration of subject participation is 10-12 weeks. This study will consist of two 2-day intervention visits separated by approximately 8 weeks.
Primary Outcome
Primary endpoint will be the within person difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two; investigators will compare this difference between the two treatment conditions
Interventions
- DRUG intra-nasal naloxone
- DRUG Intra-nasal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-06 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
Why NCT02700048 stopped before completion
NCT02700048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which intra-nasal naloxone is the first listed.
NCT02700048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02700048 about?
NCT02700048 is a clinical study titled "Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia". This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 indi...
What is the current status of trial NCT02700048?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-06. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02700048?
The interventions under investigation include: intra-nasal naloxone (DRUG), Intra-nasal saline (DRUG).
Who is sponsoring clinical trial NCT02700048?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02700048's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia